FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285587908> ?p ?o ?g. }

• W4285587908 abstract "Abstract Background Nafamostat mesylate (nafamostat, NM) is an FDA-approved serine protease inhibitor that exerts anti-neuroinflammation and neuroprotective effects following rat spinal cord injury (SCI). However, clinical translation of nafamostat has been limited by an unclear administration time window and mechanism of action. Methods Time to first dose of nafamostat administration was tested on rats after contusive SCI. The optimal time window of nafamostat was screened by evaluating hindlimb locomotion and electrophysiology. As nafamostat is a serine protease inhibitor known to target thrombin, we used argatroban (Arg), a thrombin-specific inhibitor, as a positive control in the time window experiments. Western blot and immunofluorescence of thrombin expression level and its enzymatic activity were assayed at different time points, as well its receptor, the protease activated receptor 1 (PAR1) and downstream protein matrix metalloproteinase-9 (MMP9). Blood–spinal cord barrier (BSCB) permeability leakage indicator Evans Blue and fibrinogen were analyzed along these time points. The infiltration of peripheral inflammatory cell was observed by immunofluorescence. Results The optimal administration time window of nafamostat was 2–12 h post-injury. Argatroban, the thrombin-specific inhibitor, had a similar pattern. Thrombin expression peaked at 12 h and returned to normal level at 7 days post-SCI. PAR1, the thrombin receptor, and MMP9 were significantly upregulated after SCI. The most significant increase of thrombin expression was detected in vascular endothelial cells (ECs). Nafamostat and argatroban significantly downregulated thrombin and MMP9 expression as well as thrombin activity in the spinal cord. Nafamostat inhibited thrombin enrichment in endothelial cells. Nafamostat administration at 2–12 h after SCI inhibited the leakage of Evans Blue in the epicenter and upregulated tight junction proteins (TJPs) expression. Nafamostat administration 8 h post-SCI effectively inhibited the infiltration of peripheral macrophages and neutrophils to the injury site. Conclusions Our study provides preclinical information of nafamostat about the administration time window of 2–12 h post-injury in contusive SCI. We revealed that nafamostat functions through inhibiting the thrombin-mediated BSCB breakdown and subsequent peripheral immune cells infiltration." @default.
• W4285587908 created "2022-07-16" @default.
• W4285587908 creator A5004211599 @default.
• W4285587908 creator A5014017039 @default.
• W4285587908 creator A5017067157 @default.
• W4285587908 creator A5018196058 @default.
• W4285587908 creator A5019709159 @default.
• W4285587908 creator A5021384155 @default.
• W4285587908 creator A5043886895 @default.
• W4285587908 creator A5055538346 @default.
• W4285587908 creator A5056235310 @default.
• W4285587908 creator A5058307350 @default.
• W4285587908 creator A5062728630 @default.
• W4285587908 creator A5065050299 @default.
• W4285587908 creator A5072675499 @default.
• W4285587908 creator A5073110763 @default.
• W4285587908 creator A5091543149 @default.
• W4285587908 date "2022-07-16" @default.
• W4285587908 modified "2023-10-18" @default.
• W4285587908 title "Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood–spinal cord barrier breakdown during acute spinal cord injury in rats" @default.
• W4285587908 cites W1700447009 @default.
• W4285587908 cites W1737750271 @default.
• W4285587908 cites W1804515651 @default.
• W4285587908 cites W1977186831 @default.
• W4285587908 cites W1986490107 @default.
• W4285587908 cites W1990277219 @default.
• W4285587908 cites W2005015911 @default.
• W4285587908 cites W2008996296 @default.
• W4285587908 cites W2015412261 @default.
• W4285587908 cites W2031044940 @default.
• W4285587908 cites W2041774417 @default.
• W4285587908 cites W2042729398 @default.
• W4285587908 cites W2052333415 @default.
• W4285587908 cites W2060928497 @default.
• W4285587908 cites W2061177943 @default.
• W4285587908 cites W2070460125 @default.
• W4285587908 cites W2073804293 @default.
• W4285587908 cites W2082425026 @default.
• W4285587908 cites W2096769354 @default.
• W4285587908 cites W2100771859 @default.
• W4285587908 cites W2120143347 @default.
• W4285587908 cites W2155198114 @default.
• W4285587908 cites W2161903515 @default.
• W4285587908 cites W2170645579 @default.
• W4285587908 cites W2222083162 @default.
• W4285587908 cites W2266499934 @default.
• W4285587908 cites W2302006867 @default.
• W4285587908 cites W2337694833 @default.
• W4285587908 cites W2378453630 @default.
• W4285587908 cites W2463268415 @default.
• W4285587908 cites W2487713159 @default.
• W4285587908 cites W2493204924 @default.
• W4285587908 cites W2604098146 @default.
• W4285587908 cites W2783714598 @default.
• W4285587908 cites W2791348807 @default.
• W4285587908 cites W2791650497 @default.
• W4285587908 cites W2793900597 @default.
• W4285587908 cites W2807183210 @default.
• W4285587908 cites W2810902145 @default.
• W4285587908 cites W2883644103 @default.
• W4285587908 cites W2920543411 @default.
• W4285587908 cites W2921884239 @default.
• W4285587908 cites W2950391772 @default.
• W4285587908 cites W2998193103 @default.
• W4285587908 cites W2999946782 @default.
• W4285587908 cites W3007449185 @default.
• W4285587908 cites W3013502527 @default.
• W4285587908 cites W3036195803 @default.
• W4285587908 cites W3047039431 @default.
• W4285587908 cites W3092445280 @default.
• W4285587908 cites W3111030686 @default.
• W4285587908 cites W3117266737 @default.
• W4285587908 cites W3132543173 @default.
• W4285587908 cites W3136323174 @default.
• W4285587908 cites W3154490924 @default.
• W4285587908 cites W3154552995 @default.
• W4285587908 cites W3163882711 @default.
• W4285587908 cites W3211084288 @default.
• W4285587908 cites W4230916704 @default.
• W4285587908 cites W4295334631 @default.
• W4285587908 doi "https://doi.org/10.1186/s12974-022-02531-w" @default.
• W4285587908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35842640" @default.
• W4285587908 hasPublicationYear "2022" @default.
• W4285587908 type Work @default.
• W4285587908 citedByCount "8" @default.
• W4285587908 countsByYear W42855879082022 @default.
• W4285587908 countsByYear W42855879082023 @default.
• W4285587908 crossrefType "journal-article" @default.
• W4285587908 hasAuthorship W4285587908A5004211599 @default.
• W4285587908 hasAuthorship W4285587908A5014017039 @default.
• W4285587908 hasAuthorship W4285587908A5017067157 @default.
• W4285587908 hasAuthorship W4285587908A5018196058 @default.
• W4285587908 hasAuthorship W4285587908A5019709159 @default.
• W4285587908 hasAuthorship W4285587908A5021384155 @default.
• W4285587908 hasAuthorship W4285587908A5043886895 @default.
• W4285587908 hasAuthorship W4285587908A5055538346 @default.
• W4285587908 hasAuthorship W4285587908A5056235310 @default.
• W4285587908 hasAuthorship W4285587908A5058307350 @default.
• W4285587908 hasAuthorship W4285587908A5062728630 @default.
• W4285587908 hasAuthorship W4285587908A5065050299 @default.

• next